agilon health, Inc. (AGL)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$93.59+2.43%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Agilon Health is improving its profit. Operating income rose to $4M in Q1. Cash from operations turned positive at $24M. Revenue is expected near $5.7B in 2026.
Revenue is falling and needs to stabilize. The company still loses money. Profit pressures could hurt future results.
The price is about 41% below our fair value near $182. Analysts expect 3% revenue growth. Our view is more optimistic than the Street.
Breaks if: Cash from operations falls below $0 in any quarter next year
Breaks if: Operating income falls below $0 in any quarter next year
Breaks if: Annual revenue falls below $5.68B in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
AGL represents a turnaround investment, as it is working to improve its financial health after a period of losses. The current thesis state is mixed, reflecting both recent strong performance and ongoing risks.
The market appears to price AGL as justified, with a low fragility tier. It is seen as relatively cheap compared to peers, but there is an expectations gap indicating that some improvement is anticipated.
Management is focused on increasing revenues and margins, which have shown improvement recently. However, the path to achieving positive operating and net income remains mixed, and cash flow is still negative but improving.
Key factors include the company's ability to maintain momentum in revenue and margin growth, as well as external influences like sector performance and economic conditions. Any reversal in guidance could significantly impact credibility.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The next 1-3 years will depend on AGL's execution on its priorities and the broader economic environment. Not investment advice.